-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, November 12, 2021/PRNewswire/ - Hetero, a world-renowned vertically integrated pharmaceutical organization, and Shenzhen Beimei Pharmaceuticals jointly announced that they have obtained oseltamivir phosphate from the Chinese drug regulatory agency, the National Medical Products Administration.
Oseltamivir phosphate is an antiviral drug used to treat acute uncomplicated influenza infections in adults, adolescents, and children (2 weeks of age and older)
According to WHO estimates, seasonal influenza alone may cause 290,000 to 650,000 deaths each year due to respiratory diseases
Dr.
Ms.
About Hetero
Hetero is a world-renowned vertically integrated pharmaceutical organization engaged in the research and development, manufacturing and marketing of high-quality chemical and biological drugs in different therapeutic fields
About Shenzhen Beimei Pharmaceutical Co.
Shenzhen Beimei Pharmaceutical Co.
Source: Hetero and Shenzhen Beimei Pharmaceutical Co.